Acrobiosystems Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021
April 13, 2022
Share
Acrobiosystems Co.,Ltd. reported earnings results for the full year ended December 31, 2021. For the full year, the company reported sales was CNY 376.71 million compared to CNY 239.78 million a year ago. Revenue was CNY 384.99 million compared to CNY 246.32 million a year ago. Net income was CNY 174.21 million compared to CNY 115.88 million a year ago. Basic earnings per share from continuing operations was CNY 2.7507 compared to CNY 1.9314 a year ago. Diluted earnings per share from continuing operations was CNY 2.7507 compared to CNY 1.9314 a year ago.
Acrobiosystems Co Ltd is a China-based company specializing in providing recombinant protein and other key biological reagent products and technical services. The Company's main products are recombinant proteins and detection services, as well as kits, antibodies, fillers, culture media and other related products. The Company's main products and services are applied to research and development (R&D) and production links such as early drug discovery and verification, drug screening and optimization, development and optimization of diagnostic reagents, preclinical and clinical trials, drug production process and process control (CMC) of tumors, autoimmune diseases, cardiovascular diseases, infectious diseases and other diseases.
ACROBIOSYSTEMS CO.,LTD. 
